Edwards Lifesciences Corporation (NYSE: EW) reported Q2 EPS of $1.24, $0.10 better than the analyst estimate of $1.14. Revenue for the quarter came in at $972.1 million versus the consensus estimate of $969.02 million.

GUIDANCE:

Edwards Lifesciences Corporation sees Q3 2018 EPS of $0.93-$1.03, versus the consensus of $1.08. Edwards Lifesciences Corporation sees Q3 2018 revenue of $900-950 million, versus the consensus of $933.98 million.

Edwards Lifesciences Corporation sees FY2018 EPS of $4.60-$4.75, versus the consensus of $4.63. Edwards Lifesciences Corporation sees FY2018 revenue of $3.5-3.9 billion, versus the consensus of $3.84 billion.

For earnings history and earnings-related data on Edwards Lifesciences Corporation (EW) click here.